Point72 Asset Management, L.P. 13D/13G Filings for Inhibikase Therapeutics, Inc. (IKT)

Point72 Asset Management, L.P. 13D and 13G filings for Inhibikase Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2025-02-14
4:08 pm
Sale
2024-12-31 13G Inhibikase Therapeutics, Inc.
IKT
Point72 Asset Management, L.P. 0
0.000%
-625,000decrease
(Position Closed)
Filing
2024-10-10
4:10 pm
Purchase
2024-10-09 13G Inhibikase Therapeutics, Inc.
IKT
Point72 Asset Management, L.P. 625,000
8.400%
625,000increase
(New Position)
Filing